RSS Feeds Mobile Login | Register | Subscribe

Collections

For Authors

Journal Info

Subscribe

ISPOR

VIHRI

More Periodicals

All Content

Search Advanced Search

< Previous Article

Articles and Issues

November 2015 Volume 18, Issue 7, Page A846

Next Article >

Short And Long-Term Economic Impact of Secondary Hyperparathyroidism Treatment in Chronic Kidney Disease in Carlos Andrade Marin Hospital (Ecuador)

L Manjarres, P Sanchez, M Cabezas, G Padilla, M Fornasini, A Albert

DOI: http://dx.doi.org/10.1016/j.jval.2015.09.404

Abstract Full Text

The treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) is generating high costs worldwide mainly due to adverse complications. In Ecuador, only few healthcare institutions have implemented management protocols for the treatment of SHPT to reduce costs and to improve patient quality of life. The goal of this study was to evaluate the short (1 year) and long-term (5 years) costs and savings in the management of SHPT with calcitriol and paricalcitol in CKD patients.

Log In

Email/Username:

Password:

Remember me

Forgot password?

Register

Create a new account

Purchase access to this article

• \$35.95 USDIPDF Download and 24 Hours Online Access

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.

© 2015 Published by Elsevier Inc

Access this article on ScienceDirect

Article Tools

PDF (53 KB)

Email Article

Add to My Reading List

Export Citation

Create Citation Alert

Cited by in Scopus (0) Request Permissions

Order Reprints (100 minimum order)

Early Timing Of The Use Of Paricalcitol For The Treatment Of Secondary Hyperparathyroidism (Shpt) In Chronic Kidney Patients (Ckd): A Budget Impact Analysis (Bi) Value in Health, Vol. 17, Issue 3

A Budget Impact Analysis (Bia) Of The Use Of Paricalcitol For The Treatment Of Secondary Hyperparathyroidism (Shpt) In End Stage Renal Disease Patients

Value in Health, Vol. 17, Issue 7

Long-Term Cost Comparison Between Paricalcitol and Calcitriol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in Mexico Value in Health, Vol. 16, Issue 7

PUK9 COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM: THE **EXPERIENCE IN ITALY** Value in Health, Vol. 8, Issue 6

PUK15 A Simulation Model of The Effects of Treatments for Secondary Hyperparathyroidism on Mortality Value in Health, Vol. 14, Issue 7